Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH

December 8, 2008

CHESHIRE, Conn., Dec. 8 /PRNewswire-FirstCall/ — Alexion Pharmaceuticals,
Inc. (Nasdaq: ALXN) today reported positive results from AEGIS, an open-label
registration study examining Soliris(R) (eculizumab) treatment of Japanese
patients with paroxysmal nocturnal hemoglobinuria (PNH). The pre-specified
primary efficacy endpoint of change in hemolysis was achieved with an 86
percent reduction (P<0.001). Key secondary endpoints including fatigue
(P<0.001) and transfusions/anemia (P<0.001) were also achieved.

Top-line results from AEGIS were presented today at the 50th Annual
Meeting of the American Society of Hematology in San Francisco in a poster
session titled, “Safety and Efficacy of the Terminal Complement Inhibitor
Eculizumab in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria:
AEGIS Phase II Clinical Study Results.” The study was conducted to evaluate
the safety and efficacy of Soliris in Japanese patients with PNH relative to
the previously reported SHEPHERD and TRIUMPH (1,2) Phase III Soliris trials,
which were conducted in the United States, Europe and Australia.

“These results show clinical improvements from eculizumab for Japanese
patients with PNH, consistent with those observed in the clinical trials
conducted in the United States and Europe,” said Yuzuru Kanakura, M.D., Ph.D.,
Professor of Hematology and Oncology at Osaka University Hospital in Suita,
, and lead author of the study. “Consistent with the results from the
SHEPHERD and TRIUMPH trials, these patients experienced significant reductions
in hemolysis, anemia, transfusion dependence, and fatigue. Perhaps most
noteworthy was the improvement in kidney function observed with eculizumab
treatment. These are important and potentially life-changing improvements for
patients with PNH.”

Clinical Data

In the AEGIS open-label clinical study, investigators examined the safety
and efficacy of Soliris in Japanese patients with PNH relative to the SHEPHERD
and TRIUMPH studies. The primary endpoints of the study were reduction of
hemolysis and safety following 12 weeks of Soliris treatment. The AEGIS study
included 29 patients at nine institutions with minimal transfusion
requirements (one or more transfusion episodes in the preceding two years) and
permitted enrollment of patients with significant thrombocytopenia (platelet
counts greater than or equal to 30×10(9)/L). Forty-five percent of the AEGIS
patients had a history of aplastic anemia or myelodysplastic syndromes.
Patients were dosed in accordance with the Soliris product labels approved in
the United States and European Union in 2007.

Key clinical efficacy data from the AEGIS trial presented at the ASH
meeting included:

    -- Hemolysis, the primary trial endpoint, was rapidly and significantly
       reduced with Soliris treatment. A standard measure of hemolysis,
       lactate dehydrogenase (LDH), decreased 86 percent from a median of
       1,814 U/L at baseline to a median of 244 U/L following 12 weeks of
       treatment (P<0.001; normal range 103-223 U/L).
    -- Control of hemolysis resulted in an improvement in anemia as indicated
       by a reduction in packed red blood cell (PRBC) transfusion
       requirements. Transfusions were reduced 71 percent from a mean (SE) of
       5.2 (+/-1.04) PRBC units/patient during the 12-week pre-treatment
       period to 1.5 (+/-0.67) units/patient following 12 weeks of Soliris
       treatment (P<0.001 for the pre-specified median change). Transfusion
       independence was achieved in 67 percent (14/21) of patients who were
       transfusion dependent prior to treatment (P<0.001).
    -- The improvement in anemia with Soliris treatment was also indicated by
       increased hemoglobin levels. Hemoglobin levels increased from a median
       of 7.6 g/dL (7.9 +/- 0.3) at baseline to a median of 9.0 g/dL (8.9 +/-
       0.4) following 12 weeks of Soliris treatment (P<0.001).
    -- Patient fatigue levels, as measured by the FACIT-Fatigue instrument,
       significantly improved within one week of  Soliris treatment, with a
       median increase of 5.0 points at 12 weeks (P<0.001).  A change of three
       or more points is considered clinically meaningful.
    -- An exploratory analysis was also performed to evaluate the effect of
       Soliris on Chronic Kidney Disease (CKD), measured as an improvement or
       worsening in CKD stage during treatment according to the KDOQI CKD
       published guidelines. (3) Chronic eculizumab treatment was associated
       with a 12-fold likelihood of an improvement in CKD level (P<0.001;CKD
       improved in 41 percent (12/29) of patients, CKD was unchanged in 55
       percent (16/29), CKD worsened in 3.4 percent (1/29)).

The drug appeared to be safe and well tolerated in study patients. The
most frequent adverse events (AEs) were headache (52 percent), nasopharyngitis
(41 percent), and nausea (21 percent). Most AEs were mild to moderate in
severity. No serious AEs related to study drug were reported following
treatment with Soliris.

“The AEGIS results show that Soliris treats the hallmarks of PNH in
Japanese patients with levels of safety and efficacy consistent with those
demonstrated in U.S. and European study populations,” said Leonard Bell, M.D.,
Chief Executive Officer of Alexion. “This is an important step in the process
of bringing Soliris to the substantial numbers of patients with PNH in Japan,
which is tied to our objective that every patient who can benefit from Soliris
will have access to Soliris.”

The AEGIS study was authorized by Japan’s Pharmaceutical and Medical
Device Administration (PMDA). Alexion expects to include data from the AEGIS
study in an application for marketing authorization to be submitted to the
PMDA in 2009. The Company has begun to establish its commercial organization
in Japan in anticipation of a commercial launch of Soliris in that country in

About PNH

PNH is a rare blood disorder that affects an estimated 8,000 to 10,000
people in North America and Europe and, using similar prevalence estimates,
potentially 1,000 – 2,000 patients in Japan. (4) PNH strikes people of all
ages, with an average age of onset in the early 30s. (5) Approximately 10
percent of all patients first develop symptoms at 21 years of age or younger.
(6) PNH develops without warning and can occur in men and women of all races,
backgrounds and ages. PNH often goes unrecognized, with delays in diagnosis
ranging from one to more than 10 years. (7) The estimated median survival for
PNH patients is between 10 and 15 years from the time of diagnosis. (5,7)

PNH has been identified more commonly among patients with disorders of the
bone marrow, including aplastic anemia (AA) and myelodysplastic syndromes
(MDS). (8,9,10) In patients with thrombosis of unknown origin, PNH may be an
underlying cause. (6,11)

Prior to approval of Soliris, there were no therapies specifically
available for the treatment of PNH. PNH treatment was limited to symptom
management through periodic blood transfusions, non-specific immunosuppressive
therapy and, infrequently, bone marrow transplantations — a procedure that
carries considerable mortality risk. (6,11)

About Soliris

Soliris was approved in March 2007 by the U.S. Food and Drug
Administration (FDA) as the first treatment for PNH, a rare, debilitating and
life-threatening blood disorder defined by hemolysis, or the destruction of
red blood cells. In June 2007, the European Commission (EC) also approved the
use of Soliris for the treatment of patients with PNH. Soliris is the first
therapy approved in Europe for the treatment of PNH and was the first
medicinal product to receive EC approval under the EMEA Accelerated Assessment

Important Safety Information

Soliris is generally well tolerated. The most frequent adverse events
observed in clinical studies were headache, nasopharyngitis (a runny nose),
back pain and nausea. Treatment with Soliris should not alter anticoagulant
management because the effect of withdrawal of anticoagulant therapy during
Soliris treatment has not been established.

The U.S. product label for Soliris also includes a boxed warning: “Soliris
increases the risk of meningococcal infections. Vaccinate patients with a
meningococcal vaccine at least two weeks prior to receiving the first dose of
Soliris; revaccinate according to current medical guidelines for vaccine use.
Monitor patients for early signs of meningococcal infections, evaluate
immediately if infection is suspected, and treat with antibiotics if
necessary.” During clinical studies, two out of 196 vaccinated PNH patients
treated with Soliris experienced a serious meningococcal infection.

Prior to beginning Soliris therapy, all patients and their prescribing
physicians are enrolled in the Soliris Safety Registry, which is part of a
special risk-management program that involves initial and continuing education
and long-term monitoring for detection of new safety findings.

Please see full prescribing information at www.soliris.net.

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to
develop and deliver life-changing drug therapies for patients with serious and
life-threatening medical conditions. Alexion is engaged in the discovery,
development and commercialization of therapeutic products aimed at treating
patients with a wide array of severe disease states, including hematologic
diseases, cancer, and autoimmune disorders. In March 2007, the FDA granted
marketing approval for Alexion’s first product, Soliris, for all patients with
PNH, and Alexion began commercial sale of Soliris in the U.S. during April
. In June 2007, the EC granted marketing approval for Soliris in the
European Union for all patients with PNH. Alexion is evaluating other
potential indications for Soliris as well as other formulations of eculizumab
for additional clinical indications, and is pursuing development of other
antibody product candidates in early stages of development. This press release
and further information about Alexion Pharmaceuticals, Inc. can be found at:


Safe Harbor Statement

This news release contains forward-looking statements, including
statements related to potential health and medical benefits from Soliris and
the timing of regulatory and commercial milestones for Soliris in Japan.
Forward-looking statements are subject to factors that may cause Alexion’s
results and plans to differ from those expected, including for example,
decisions of regulatory authorities regarding marketing approval or material
limitations on the marketing of Soliris, delays in arranging satisfactory
manufacturing capability and establishing commercial infrastructure, delays in
developing or adverse changes in commercial relationships, the possibility
that results of clinical trials are not predictive of safety and efficacy
results of Soliris in broader patient populations, the possibility that
initial results of commercialization are not predictive of future rates of
adoption of Soliris, the risk that third parties won’t agree to license any
necessary intellectual property to Alexion on reasonable terms or at all, the
risk that third party payors will not reimburse for the use of Soliris at
acceptable rates or at all, the risk that estimates regarding the number of
PNH patients are inaccurate, the risk that pending litigation may be resolved
adversely, and a variety of other risks set forth from time to time in
Alexion’s filings with the Securities and Exchange Commission, including but
not limited to the risks discussed in Alexion’s Quarterly Report on Form 10-Q
for the period ended September 30, 2008, and in Alexion’s other filings with
the Securities and Exchange Commission. Alexion does not intend to update any
of these forward-looking statements to reflect events or circumstances after
the date hereof, except when a duty arises under law.

    (1)  Brodsky RA, Young, NS, Antonioli E, et al. Multicenter phase 3 study
         of the complement inhibitor eculizumab for the treatment of patients
         with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840-1847.
    (2)  Hillmen P, Young NS, Schubert J, et al. The complement inhibitor
         eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med.
    (3)  Levey AS, Coresh J, Balk E, et al. National Kidney Foundation
         Practice Guidelines for Chronic Kidney Disease: evaluation,
         classification, and stratification. Ann Intern Med. 2003;139:137
    (4)  Hill A, Platts PJ, Smith A et al. The incidence and prevalence of
         paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients
         in Yorkshire [abstract]. Blood. 2006;108(11):985.
    (5)  Socie G, Mary J Yves, de Gramont A, et al. Paroxysmal nocturnal
         haemoglobinuria: long-term follow-up and prognostic factors. Lancet.
         1996: 348:573-577.
    (6)  Parker C, Omine M, Richards S, et al. Diagnosis and management of
         paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699-3709.
    (7)  Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural
         history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;
    (8)  Wang H, Chuhjo T, Yasue S, Omine M, Naka S. Clinical significance of
         a minor population of paroxysmal nocturnal hemoglobinuria-type cells
         in bone marrow failure syndrome. Blood. 2002;100 (12):3897-3902.
    (9)  Iwanga M, Furukawa K, Amenomori T, et al. Paroxysmal nocturnal
         haemoglobinuria clones in patients with myelodysplastic syndromes.
         Br J Haematol. 1998;102 (2):465-474.
    (10) Maciejewski JP, Risitano AM, Sloand EM, et al. Relationship between
         bone marrow failure syndromes and the presence of glycophosphatidyl
         inositol-anchored protein-deficient clones. Br J Haematol.
    (11) Hill A, Richards S, Hillmen P. Recent developments in the
         understanding and management of paroxysmal nocturnal
         haemoglobinuria. Br J Haematol. 2007;137 (3):181-192.

    Poster: III-520

SOURCE Alexion Pharmaceuticals, Inc.

Source: newswire

comments powered by Disqus